A Phase 1 interventional study of SUZ in Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 1 site in United States. Open to participants aged 25 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing suzetrigine in Pain — 4 open to participants now, 4 under way, 2 of them phase 3. suzetrigine · Pain.
Among the 21 studies testing suzetrigine in Pain, this one is the 21st largest by enrollment, is one of 5 that started in 2025, is one of 15 in phase 1, and was the 12th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →4 of the 21 studies testing suzetrigine in Pain are open now, in 1 country. Recruiting first, the newest first:
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
Stanford University · Sites in United States
Ages 18+
Jacob Lensing · Sites in United States
Ages 18–45
By country, each count listing its studies:
suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 25 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 5 started in 2025.
This study's enrollment of 10 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 50 across the 21 interventional studies. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
26 studies in Pain by Vertex Pharmaceuticals Incorporated: none open now, none under way, none of them phase 3. Of 26 finished, 1 (4%) have results posted.
Among the 26 studies in Pain by Vertex Pharmaceuticals Incorporated, this one is the 25th largest by enrollment, is one of 3 that started in 2025, is one of 24 in phase 1, and was the 22nd registered.
Vertex Pharmaceuticals Incorporated’s Pain studies by the year they started, since 2022.
2 of the studies testing suzetrigine in Pain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226700Phase 3Hospital for Special Surgery, New YorkSuzetrigine in Total Hip Arthroplasty | 2027-11-01 |
| NCT07821931Stanford UniversitySuzetrigine in Tonsillectomy for Opioid-sparing Pain Management | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies testing suzetrigine in Pain, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 26 in Pain:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the sensory attributes (basic tastes, aroma, texture, mouthfeel) of SUZ SDD and assess the impact of the dose on the sensory attributes.
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4) (A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Participants will be given SUZ SDD to retain in their mouths for approximately 10 seconds and then expectorate.
Drug: SUZ
Powder for oral administration.
Also known as: VX-548
Flavor Assessment Based on Flavor Profile Method of Descriptive Sensory Analysis per American Society for Testing and Material (ASTM) Approved Sensory Evaluation Method
Time frame: Periodic Intervals up to 30 minutes post oral administration
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Apr 2025, 1 month.
Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 1 month is below that.
Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suzetrigine
Vertex Pharmaceuticals Incorporated →